« Return to News | Drug Sponsors

Analysts eye Pfizer break-up

Monday, May 2, 2011 01:22 PM

Analysts have been eyeing the prospect of a Pfizer break-up; they figure Pfizer would be worth $180 billion in pieces, according to Fierce Pharma.

Fierce notes some of Forbes quotes for potential prices of Pfizer units--animal health, $16 billion; nutritionals, $8 billion; and consumer health, $6 billion; established products business, which sells off-patent drugs, $40 billion.  The rest of core business would be estimated at $110 billion.

The divestment is creating lots of buzz, even though the strategic review of Pfizer assets will likely continue for the rest of this year.  CEO Ian Read seems to be leaning toward some sell-offs, reports Fierce Pharma. "My sense is he's already made up his mind," says Goldman Sachs analyst Jami Rubin, who's been calling for a Pfizer break-up for years.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.